Citadel Advisors’s Genetic Technologies Ltd. GENE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-682
| Closed | -$510 | – | 15791 |
|
|
2024
Q3 | $510 | Buy |
+682
| New | +$606 | ﹤0.01% | 14007 |
|
|
2023
Q2 | – | Sell |
-242
| Closed | -$1.41K | – | 15478 |
|
|
2023
Q1 | $1.41K | Buy |
+242
| New | +$1.42K | ﹤0.01% | 14304 |
|
|
2022
Q3 | – | Sell |
-7,223
| Closed | -$41K | – | 13874 |
|
|
2022
Q2 | $41K | Buy |
7,223
+4,831
| +202% | +$34.9K | ﹤0.01% | 12057 |
|
|
2022
Q1 | $24K | Sell |
2,392
-4,819
| -67% | -$46.8K | ﹤0.01% | 13200 |
|
|
2021
Q4 | $68K | Sell |
7,211
-883
| -11% | -$11.3K | ﹤0.01% | 13058 |
|
|
2021
Q3 | $125K | Buy |
8,094
+2,724
| +51% | +$46.7K | ﹤0.01% | 12597 |
|
|
2021
Q2 | $114K | Sell |
5,370
-15,628
| -74% | -$315K | ﹤0.01% | 12797 |
|
|
2021
Q1 | $438K | Buy |
20,998
+16,183
| +336% | +$370K | ﹤0.01% | 9983 |
|
|
2020
Q4 | $87K | Buy |
+4,815
| New | +$79.5K | ﹤0.01% | 10302 |
|
|
2019
Q3 | – | Sell |
-2,258
| Closed | -$27K | – | 9890 |
|
|
2019
Q2 | $27K | Buy |
2,258
+619
| +38% | +$9.53K | ﹤0.01% | 8895 |
|
|
2019
Q1 | $29K | Sell |
1,639
-59
| -3% | -$979 | ﹤0.01% | 9005 |
|
|
2018
Q4 | $18K | Buy |
1,698
+1,120
| +194% | +$23.2K | ﹤0.01% | 8793 |
|
|
2018
Q3 | $13K | Buy |
+578
| New | +$13.1K | ﹤0.01% | 9088 |
|
|
2018
Q2 | – | Sell |
-893
| Closed | -$19K | – | 9403 |
|
|
2018
Q1 | $19K | Buy |
+893
| New | +$25.8K | ﹤0.01% | 8133 |
|
|
2017
Q3 | – | Sell |
-1,279
| Closed | -$23K | – | 8178 |
|
|
2017
Q2 | $23K | Buy |
1,279
+726
| +131% | +$15.2K | ﹤0.01% | 7258 |
|
|
2017
Q1 | $13K | Buy |
+553
| New | +$12.6K | ﹤0.01% | 7326 |
|
|
2016
Q4 | – | Sell |
-532
| Closed | -$19K | – | 7985 |
|
|
2016
Q3 | $19K | Buy |
+532
| New | +$21.7K | ﹤0.01% | 7073 |
|
|
2016
Q2 | – | Sell |
-818
| Closed | -$38K | – | 7543 |
|
|
2016
Q1 | $38K | Buy |
+818
| New | +$35.6K | ﹤0.01% | 6318 |
|
|
2015
Q4 | – | Sell |
-636
| Closed | -$23K | – | 9317 |
|
|
2015
Q3 | $23K | Sell |
636
-80
| -11% | -$4.29K | ﹤0.01% | 8071 |
|
|
2015
Q2 | $44K | Sell |
716
-1,321
| -65% | -$111K | ﹤0.01% | 7744 |
|
|
2015
Q1 | $215K | Buy |
+2,037
| New | +$167K | ﹤0.01% | 6094 |
|
|
2014
Q4 | – | Sell |
-148
| Closed | -$8K | – | 8791 |
|
|
2014
Q3 | $8K | Sell |
148
-37
| -20% | -$2.89K | ﹤0.01% | 7812 |
|
|
2014
Q2 | $20K | Sell |
185
-279
| -60% | -$33.4K | ﹤0.01% | 7288 |
|
|
2014
Q1 | $65K | Buy |
+464
| New | +$74.2K | ﹤0.01% | 6556 |
|
Other funds holding GENE
Citadel Advisors's GENE Position: Q4 2024 in Review
Citadel Advisors sold out of Genetic Technologies Ltd. (GENE) in Q4 2024, closing a stake of 682 shares — an estimated $510 sold.
Citadel Advisors first reported a position in GENE in Q1 2014 and held it in 24 quarters. The position peaked at $438K in Q1 2021. 1 fund tracked by Wall St. Rank holds GENE as of Q4 2024.
- Citadel Advisors reported no remaining Genetic Technologies Ltd. position as of Q4 2024 after selling out during the quarter.
- Citadel Advisors sold 682 Genetic Technologies Ltd. shares in Q4 2024, an estimated $510.
- Citadel Advisors first reported a position in Genetic Technologies Ltd. in Q1 2014 and held it in 24 quarters.
- Citadel Advisors's Genetic Technologies Ltd. position peaked at $438K in Q1 2021.
- 1 fund tracked by Wall St. Rank held Genetic Technologies Ltd. as of Q4 2024.
Based on Citadel Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.